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ABSTRACT 
SATB2-associated syndrome (SAS) is an autosomal dominant neurodevelopmental 
disorder caused by alterations in the SATB2 gene. Here we present a review of published 
pathogenic variants in the SATB2 gene to date and report 38 novel alterations found in 57 
additional previously unreported individuals. Overall, we present a compilation of 120 
unique variants identified in 155 unrelated families ranging from single nucleotide coding 
variants to genomic rearrangements distributed throughout the entire coding region of 
SATB2. Single nucleotide variants predicted to result in the occurrence of a premature 
stop codon were the most commonly seen (51/120=42.5%) followed by missense variants 
(31/120=25.8%). We review the rather limited functional characterization of pathogenic 
variants and discuss current understanding of the consequences of the different molecular 
alterations. We present an expansive phenotypic review along with novel genotype-
phenotype correlations. Lastly, we discuss current knowledge on animal models and 
present future prospects. This review should help provide better guidance for the care of 
individuals diagnosed with SAS. 
Graphical Abstract 
SATB2-associated syndrome (SAS) is an autosomal dominant neurodevelopmental 
disorder. In this mutation update we review the current state of our knowledge of SATB2 
mutations and present 38 novel alterations. We examine the molecular and phenotypic 
findings and discuss the genotype-phenotype correlation. 
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Key Words: SATB2-Associated syndrome, SATB2, genotype-phenotype correlation, 
pathogenic variants, whole exome sequencing 
1. BACKGROUND 
SATB2-associated syndrome (SAS; Glass syndrome, MIM# 612313) is an autosomal 
dominant disorder first reported in 1989 in a 16-year-old male with severe intellectual 
disability and an interstitial deletion of 2q32.2-2q33.1 (Glass, et al., 1989). Clinically, 
SAS is characterized by developmental delay/intellectual disability with absent or limited 
speech development, palatal and dental abnormalities, feeding difficulties, behavioral 
problems, and dysmorphic facial features (Docker, et al., 2014; Zarate, et al., 2015; 
Zarate, et al., 2018a). Other supportive findings such as skeletal anomalies with low bone 
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density and abnormal brain neuroimaging have been described (Zarate, et al., 2018a; 
Zarate, et al., 2018b).  
SAS is caused by alterations of SATB2 that can include single nucleotide variants 
(loss-of-function as well as missense), intragenic deletions and duplications, contiguous 
deletions, and translocations with secondary gene disruption (Zarate and Fish, 2017; 
Zarate, et al., 1993). While haploinsufficiency of SATB2 seems the most likely 
mechanism of disease, a dominant negative effect has been suggested in at least one 
instance in an individual with a nonsense variant (Leoyklang, et al., 2013). The SATB2 
gene maps to 2q32-q33 and has 3 transcripts (NM_001172509, NM_001172517, and 
NM_015265), codes for SATB2, a 82.6 kDa protein of 733 amino acids. 
SATB2 binds to nuclear matrix-attachment regions (MARs) where it organizes 
chromatin to regulate tissue-specific gene regulatory networks (GRNs), and thus has 
critical roles in multiple developmental processes (Britanova, et al., 2006; Dobreva, et al., 
2006; Dobreva, et al., 2003; Gyorgy, et al., 2008). The SATB2 protein has two CUT 
domains and a homeodomain (FitzPatrick, et al., 2003) that are highly conserved across 
vertebrate taxa (FitzPatrick, et al., 2003; Sheehan-Rooney, et al., 2010). The CUT 
domains and homeodomains are both DNA-binding motifs, which may bind DNA 
independently or cooperatively. 
Clinically, SAS has been characterized through two large cohort studies (Bengani, 
et al., 2017; Zarate, et al., 2018a). We recently presented the common clinical features 
and natural history of 72 individuals with SAS due to a variety of molecular mechanisms. 
In this study, we review the previously described individuals with SAS and present 57 
This article is protected by copyright. All rights reserved. 
 A
cc
e
pt
e
d 
A
rt
ic
le
 
additional individuals that expand the mutation spectrum seen in this condition and 
describe novel genotype-phenotype correlations. All families reported for the first time 
were enrolled under a research clinical registry protocol approved by the Institutional 
Review Board of the University of Arkansas for Medical Sciences.  
2. VARIANTS 
All SATB2 variants are described according to current HGVS mutation nomenclature 
guidelines based on Genbank accession number NM_015265 (den Dunnen, et al., 2016). 
Novel variants are interpreted using ACMG classification recommendations (Richards, et 
al., 2015). This report excludes larger deletions and duplications that encompass SATB2 
along with adjacent genes.  
Tables 1 and 2 detail all 101 previously published SATB2 intragenic alterations in 
the international peer-reviewed literature (PubMed database) and the Human Gene 
Mutation Database (HGMD professional 2018.3) (Asadollahi, et al., 2014; 
Balasubramanian, et al., 2011; Baptista, et al., 2008; Bengani, et al., 2017; Boone, et al., 
2016; Bowling, et al., 2017; Brewer, et al., 1999; Cherot, et al., 2018; Deciphering 
Developmental Disorders Study, 2017; Farwell, et al., 2015; Gilissen, et al., 2014; Kaiser, 
et al., 2015; Kikuiri, et al., 2018; Lee, et al., 2016; Leoyklang, et al., 2007; Lieden, et al., 
2014; Lv, et al., 2018; Rainger, et al., 2014; Rauch, et al., 2012; Rosenfeld, et al., 2009; 
Schwartz, et al., 2017; Scott, et al., 2018; Talkowski, et al., 2012; Tegay, et al., 2009; 
Trakadis, et al., 2014; Vissers, et al., 2017; Zarate, et al., 2017; Zarate, et al., 2015; 
Zarate, et al., 2018a; Zarate, et al., 2018b). In this study, we also report 57 additional 
individuals with 47 SATB2 alterations (Tables 1 and 2) that have been submitted to the 
LOVD database: https://databases.lovd.nl/shared/genes/SATB2. 
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Overall, including our data and those of the literature, a total of 120 unique 
variants were found in 158 individuals from 155 unrelated families. While all types of 
pathogenic variants were found, single nucleotide variants that are predicted to result in 
the occurrence of a premature stop codon were the most commonly seen 
(51/120=42.5%). Missense variants were also frequently found (25.8%), followed by 
intragenic deletions (18.3%), translocations (5%), splice site alterations (5%), intragenic 
duplications (2.5%), and a single in-frame alteration (0.8%) (Supp. Figure S1).  
2.1 Point pathogenic variants 
Eighty-nine distinct point variants including single base substitutions and small 
deletions/insertions were found in 127 individuals from 125 families (Figure 1) (Liu, et 
al., 2015). Most molecular diagnostics were performed by whole exome sequencing 
(WES) (105/127=82.7%) with the remaining individuals obtaining the diagnosis through 
a different next generation sequencing (NGS) platform (epilepsy, intellectual disability or 
Angelman syndrome dedicated panels, 11.8%), SATB2 Sanger sequencing (3.1%), or 
whole genome sequencing (WGS, 2.4%). De novo status was confirmed in almost all 
instances when parental testing was performed (98.1%, 105/107 families), including a 
pair of monozygotic twins. The remaining two instances correspond to a pair of siblings 
found to have the same variant indicating germline mosaicism and a case of low level 
blood mosaicism in a father of a single SAS-affected individual previously reported. 
Here, we present individual (SATB2-135) with a de novo mosaic pathogenic variant 
(c.1498delG) as determined by WES (32/143 reads) and presenting with the common 
phenotypic features.  
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The 89 pathogenic variants were distributed along the entire coding sequence of 
SATB2, and while variants were present in every coding exon (exon 3-12), the 
distribution was not uniform (Supp. Figure S2A). Unique pathogenic variants found in 
single individuals were most common (Figure 1). However, 7.9% of the pathogenic 
variants (7/89) were seen in two to four different families and 4.5% (4/89) were present 
in five or more families. Nearly half (41/89=46.1%) of the pathogenic variants were 
found in exons 8 and 9. There was a clear overrepresentation of exon 9 in particular when 
adjusting by size of each individual exon. This suggests a hotspot of pathogenic variants 
(Supp. Figure S2B). 
2.1.1 Missense variants 
Thirty-one unique missense variants were found in 49 individuals. Most missense 
variants were located within exons 8 and 9 (19/31=61.3%, Supp. Figure S2A) and located 
within the CUT1 domain (17/31=54.8%) of the SATB2 protein. Missense variants were 
often shared by multiple individuals with alterations in codons 389 (12 individuals) and 
399 (7 individuals) being particularly common, suggesting hotspots. Most missense 
variants were confirmed to be de novo (44/45=97.8%). To assess the predicted 
pathogenicity of the 11 novel variants reported in this study, Polyphen2, SIFT, Provean, 
Mutation Taster, and CADD prediction programs were used (Supp. Table S1). Ten 
variants were interpreted as deleterious by all 5 programs, the remaining (p.Gln514Arg) 
with 4/5 programs predicting damaging effects.  
Functional studies have been performed for three missense variants: c.1165C>T, 
p.(Arg389Cys), c.1543G>A, p.(Gly515Ser), and c.1696G>A p.(Gln566Lys) (Bengani, et 
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al., 2017). The p.Arg389Cys change located in the CUT1 domain led to a marked 
increase in the proportion of soluble fraction of the protein while the p.Gly515Ser and 
p.Gln566Lys variants located within the CUT2 domain and the region between CUT2 
and the HOX domains respectively, had the opposite effect. These experiments suggested 
a role of the CUT1 domain in initiating interaction with chromatin and a requirement for 
the CUT2 domain to facilitate dissociation of SATB2 from bound chromatin. These 
alterations in the kinetics of chromatin association resulting from missense variants have 
been postulated to functionally result in alterations that resemble complete loss-of-protein 
function (Bengani, et al., 2017). 
2.1.2 In frame insertion 
A single de novo in frame insertion of 12 nucleotides not predicted to alter the reading 
frame has been reported in SATB2: c.929_930insTTGTAAGGCAAC, 
p.(Q310delinsHCKAT). The individual had a history of moderate to severe intellectual 
disability, autism, macrocephaly, frontal bossing, and deep-set eyes (Gilissen, et al., 
2014).  
2.1.3 Predicted truncating variants  
Fifty-one SATB2 variants reported were predicted to be disruptive to protein production 
resulting in loss of function, including 5 nonsense and 11 frameshift novel variants from 
this study. The variants were distributed throughout the reading frame but were 
frequently found within exons 8 to 12 (38/51=74.5%). Stop-gain pathogenic variants 
located within the last 2 exons might be expected to escape nonsense-mediated decay and 
result in a shorter protein. In keeping with this hypothesis, a single variant located within 
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the last exon of SATB2 (c.2074G>T; p.Glu692*) was shown to result in a shorter protein 
consistent with the predicted 692aa protein product of the mutant cDNA (Bengani, et al., 
2017). Two additional predicted loss-of-function variants have been studied in greater 
detail: c.715C>T (p.R239*) and c.847C>T (p.R283*) both found in six individuals each. 
The c.715C>T variant located in exon 8, was documented at the RNA level in two 
previously described unrelated individuals, indicating that the RNA was stable enough to 
escape nonsense mediated decay (NMD) (Docker, et al., 2014; Leoyklang, et al., 2007). 
Further, the translated truncated protein retained the SATB2 dimerization domain. 
Through luciferase assays using a MAR sequence binding domain, it was documented to 
interfere with the repressive MAR-regulated transcriptional activity of the wild-type 
SATB2, suggesting a dominant negative effect for this mutation (Leoyklang, et al., 
2013). Conversely, the c.847C>T variant, also located in exon 8, was studied from tooth 
mesenchymal cells from an affected individual. Diminished SATB2 expression by 
Sanger sequencing and reduced SATB2 mRNA compared to control was demonstrated 
for this variant, suggesting NMD of the mutant RNA transcript (Kikuiri, et al., 2018). 
2.1.4 Splice site variants  
Six variants (1 novel from this study) disrupted an essential splice site consensus 
sequence: three affecting the donor (5’) site at the end of exons 4, 5, and 8, and three 
affecting the acceptor (3’) site at the start of exons 7, 9, and 12. Splice-prediction 
programs (MaxEntScan and Human Splicing Finder) predicted abnormal splicing for all 
variants and a potential activation of cryptic donor site or acceptor site for c.473+1delG 
and c.1741-1G>A, respectively. No RNA analysis has been performed to confirm the 
impact on splicing for any of these variants.  
This article is protected by copyright. All rights reserved. 
 A
cc
e
pt
e
d 
A
rt
ic
le
 
2.2 Large intragenic rearrangements 
Twenty five SATB2 exonic (1 to 12 inclusive) rearrangements including 22 deletions (10 
from this report) and 3 duplications have been described (Table 2). For the 10 individuals 
that underwent parental testing, de novo status was confirmed. A pair of siblings 
(SATB2-02 and SATB2-128) with an intragenic deletion from phenotypically unaffected 
parents is also reported here for the first time suggesting germline mosaicism. Except for 
one individual (SATB2-92) identified through WGS and another as part of subtelomere 
multiplex ligation-dependent probe hybridization (MLPA) analysis (SATB2-140), all 
other copy number variations were initially identified by chromosomal microarray 
performed as part of the clinical evaluation with sizes ranging from 10 to 317kb for 
deletions and between 32 and 54kb for duplications (Table 2). For all individuals, SATB2 
was the only gene affected with no involvement of adjacent genes. Multi-exonic 
rearrangements were more common (19/25=76.0%) than single exon involvement (Figure 
1). Abnormalities involving at least exon 7 were present in half of these individuals (14 
total from 13 unrelated families). No deletions have been documented at the cDNA level 
and only 2 refined by MLPA. A single duplication was studied at the cDNA level 
(Kaiser, et al., 2015). In this female individual, an initial chromosomal microarray 
(Cytoscan HD, Affymetrix) revealed an 84-kb duplication within chromosomal region 
2q33.1 (200,256,583–200,340,204) encompassing a part of the SATB2 gene. Reverse 
transcription PCR analysis with cDNA primers flanking the duplicated exon and 
subsequent Sanger sequencing of the extracted cDNA fragments showed the tandem in-
frame duplication consistent with co-expression of transcripts with a duplicated exon and 
wild-type transcripts. 
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2.3 Large chromosomal rearrangements including 2q33.1 
Thirty-five individuals with larger chromosomal alterations that include 2q33.1 (33 
deletions, 2 duplications) have been reported and reviewed in the past (Zarate and Fish, 
2017; Zarate, et al., 2018a). For deletions, some of these include dozens of adjacent genes 
and are as large as 26.3 Mb (Rifai, et al., 2010). While overlapping features with SAS are 
present in most individuals with larger deletions, other less common abnormalities such 
as genitourinary anomalies, cardiac defects, and ectodermal changes (other than dental) 
appear to be more common (or exclusively present) when compared to intragenic 
molecular alterations (Zarate and Fish, 2017). For this group of individuals with larger 
rearrangements of 2q33.1, it remains difficult to establish genotype/phenotype 
correlations given the potential phenotype contribution of other genes besides SATB2.  
2.4 Translocations 
The original report of two de novo apparently balanced autosomal translocations 
t(2;7)(q33;p21) and t(2;11)(q32;p14) allowed the recognition of SATB2 as the causative 
gene for this syndrome 
(Brewer, et al., 1999). High resolution mapping of the t(2;7) translocation showed 
disruption of the coding region of the SATB2 gene between exons 2 and 3 (FitzPatrick, et 
al., 2003), whereas t(2;11) disrupted the long-range cis regulatory elements located in the 
centromeric gene desert 3’ of SATB2 (Rainger, et al., 2014). A few additional individuals 
with SATB2 disruption secondary to de novo chromosomal translocations were 
subsequently described to result in SAS providing further supporting evidence for this 
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molecular mechanism of disease (Baptista, et al., 2008; Rainger, et al., 2014; Talkowski, 
et al., 2012; Tegay, et al., 2009).  
3. BIOLOGICAL RELEVANCE 
SATB2 pathogenic alterations are distributed throughout the coding regions of the gene 
but exons 8, 9, and 11 are most commonly involved. For missense variants, most 
(23/31=74.2%) are located within the CUT1, CUT2 or HOX DNA protein domains. 
While the joint function of these DNA binding domains is not fully clear, it is suggested 
that missense variants 
within the core of the CUT domain are likely to result in loss of DNA-binding activity; 
CUT1 being required to initiate interaction with chromatin and CUT2 (and the region 
between CUT2 and HOX) required to facilitate dissociation of SATB2 from bound 
chromatin (Bengani, et al., 2017). The vast majority of pathogenic alterations of SATB2 
are null variants (frameshift, nonsense, canonical splice site, and single or multiexon 
deletions) and while predicted to result in a loss-of-function and haploinsufficiency, 
limited functional studies have suggested a potential dominant negative effect for some. 
Of note, an increasing number of missense pathogenic variants have been described with 
functional alterations that resemble the complete loss-of-protein function.  
4. CLINICAL AND DIAGNOSTIC RELEVANCE 
A summary of clinical features of all 158 individuals previously reported and from this 
report, excluding those with larger deletions and duplications that include SATB2 and 
surrounding genes, is presented in Table 3. With rare exceptions, SAS diagnosis was not 
clinically recognized a priori. However, while the diagnosis of SAS still relies on 
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molecular confirmation of a pathogenic variant in SATB2, a distinctive phenotype can 
often be identified. Speech delay is present in all individuals older than 2 years of age.  
Severe expressive language delay is common with 84.3% (102/121) of individuals older 
than 4 years of age having 10 or fewer words in their expressive vocabulary, with 42.1% 
(51/121) demonstrating completely absent verbal communication (Supp. Figure S3). 
Other areas of neurodevelopment can also be compromised as evidenced by an average 
age at first steps of 25.5 months. Intellectual disability has been reported in several 
individuals old enough to undergo cognitive evaluations and often in the moderate to 
severe range (Zarate, et al., 2018a). Dental abnormalities are present in all individuals 
and include delayed development of the mandibular second bicuspids or the roots of the 
permanent teeth, severely rotated or malformed teeth, taurodontism, and multiple 
odontomas (Kikuiri, et al., 2018; Scott, et al., 2018). Behavioral difficulties, feeding 
issues, abnormal brain neuroimaging, low bone density, suggestive facial features, and 
cleft palate complete the characteristic phenotype of SAS (Table 3). Through previous 
reports and the evaluation of dozens of patients by at least a single examiner (Y.A.Z.), 
broad thumbs and/or halluces appear to be another distinctive feature, present in a third of 
individuals evaluated (16/47=34%), that could raise the clinical suspicion of this 
diagnosis (Figure 2A).  
Since the identification of SATB2 as the gene responsible for SAS, the number of 
described individuals has continued to grow over the last few years. Most current 
molecular cytogenetic platforms should be able to detect exon level intragenic deletions 
involving SATB2. Likewise, SATB2 is part of several commercially available panels 
targeting broad phenotypes such as developmental delay, autism, or seizures. As families 
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receive counseling, it is important to discuss the potential recurrence risk considering a 
few instances of suspected germline mosaicism documented. With a previous report of 
coding variants in siblings and the sibling pair with intragenic deletions reported here, we 
estimate a 1-2% germline mosaicism risk (2/155 families=1.3%). Of note, paternal blood 
mosaicism has also been documented in one occasion. Lastly, management and 
surveillance guidelines for SAS have been proposed and typically need the participation 
of a multidisciplinary team with heavy emphasis on pediatric dentistry and speech 
therapy (Zarate and Fish, 2017; Zarate, et al., 1993). 
5. GENOTYPE/PHENOTYPE CORRELATIONS 
Supplementary table S2 presents detailed clinical features present in each of the 158 
individuals (114 individuals enrolled in the SAS registry and 44 additional reported in the 
literature). We identified differences in clinical characteristics by molecular mechanism. 
Specific changes to the gene were compared to all other changes, using either Chi-square 
or Fisher’s exact tests (when at least one cell had an expected count of less than 5) for 
categorical variables, and t-tests for continuous variables. While there were no 
differences in the average age at walking or talking, other clinically relevant distinctions 
were identified (Supp. Table S3). The proportion of individuals with no verbal words to 
communicate older than 4 years of age was lowest for nonsense variants (8/29=27.6%) 
and highest for missense pathogenic variants mutations (20/39=51.3%), (p=0.0496). 
Individuals with missense pathogenic variants were less likely to have cleft palate 
(11/49=22.5% vs 59/105=56.2% for other groups, p<0.0001) but more likely to have 
clinical seizures (14/46=30.4% vs 15/97=15.5% for other groups, p=0.0375). Conversely, 
individuals with nonsense variants had significantly fewer clinical seizures (3/35=8.6% 
This article is protected by copyright. All rights reserved. 
 A
cc
e
pt
e
d 
A
rt
ic
le
 
vs 26/108=24.1% for other groups, p=0.0474). Lastly, individuals with frameshift 
variants were more likely to have feeding difficulties (25/26=96.2% vs 64/104=61.5% for 
other groups, p=0.0007). If this difference in the prevalence of feeding difficulties is the 
result of a true biologically different mechanism for frameshift variants compared to 
nonsense variants or merely the result of an statistical anomaly, is unclear.  
To determine if facial dysmorphisms were different enough among the most common 
molecular mechanisms, 102 2D photographs from 69 individuals (19 nonsense, 31 
missense, and 19 frameshift variants) were analyzed using Face2Gene (FDNA Inc., 
Boston, MA) analytic tool vs.18.2.0. No statistically significant differences were found 
among the three composite images (Figure 2B). However, binary comparisons for each of 
the three groups against a respective age and gender matched cohort of typical 
individuals revealed statistically significant differences for all three groups (nonsense, 
p=0.04; missense, p=0.018; frameshift, p=0.019). 
6. ANIMAL MODELS 
Much of what we know about SATB2 function in human development has come 
from studies in animal models. In mice, Satb2 is expressed in tissues that are affected in 
SAS patients. During development, Satb2 is expressed in upper layer neurons, neural 
crest progenitors of the jaw, osteoblasts, odontoblasts and other dental progenitor cells 
(Britanova, et al., 2006; Dobreva, et al., 2006; He, et al., 2017). In adults, Satb2 continues 
to contribute to bone and brain function through its expression in osteoblasts and 
pyramidal neurons of the cerebral cortex and hippocampus (Huang, et al., 2013; Jaitner, 
et al., 2016; Wei, et al., 2012).  
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In general, Satb2 functions as a transcriptional regulator that is important for 
tissue-specific functions. In mice bone progenitors, Satb2 regulates osteogenic 
differentiation genes (Dobreva, et al., 2006), while in post-mitotic neurons Satb2 
regulates expression of genes involved in upper layer identity, synaptic transmission, and 
axon guidance (Jaitner, et al., 2016; Li, et al., 2017; Whitton, et al., 2018). The 
consequence of loss of Satb2 in bone progenitors is reduced bone size and density due to 
increased cell death and reduced differentiation potential (Britanova, et al., 2006; 
Dobreva, et al., 2006).  
In murine brain development, Satb2 is required to specify upper layer cortical 
neurons that project axons across the corpus callosum to the contralateral hemisphere 
(Alcamo, et al., 2008; Britanova, et al., 2008). Loss of Satb2 also results in reduced 
branches and spine density in basal dendrites of hippocampal neurons (Li, et al., 2017). 
Similar to SAS patients, Satb2+/- heterozygous mice have no reported corpus callosum 
defects (Alcamo, et al., 2008; Zarate, et al., 2018a). However, Satb2+/- heterozygous mice 
suffer from impaired working and spatial memory. This deficit is exacerbated in mice 
where Satb2 has been deleted postnatally in hippocampal neurons (Li, et al., 2017). These 
mice also have difficulties in locomotion, short-term novel object recognition memory, 
and long-term contextual fear memory (Jaitner, et al., 2016; Li, et al., 2017). 
Taken together, research in animal systems has provided molecular and cellular 
mechanisms underlying SAS pathogenesis. These data help outline expectations of long-
term care and provide medical practitioners with guidance about the potential spectrum of 
defects to manage in SAS patients. However, current treatments are symptom-guided, 
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and do not specifically target pathogenic mechanisms. Future research is needed to 
further explore potential therapies that directly target SAS pathology. 
7. FUTURE PROSPECTS 
A key avenue of future research is the use of human induced pluripotent stem 
cells (hiPSCs) to model disease and evaluate potential treatments. hiPSCs can be 
generated from patients with defined clinical phenotypes, thus enabling in vitro cellular 
phenotypes to be linked to individual clinical presentation. Use of hiPSCs allows the 
pathogenic mechanisms of different types of mutations to be evaluated. The potential to 
have hiPSCs from an unaffected parent provides a control for genetic background, 
allowing molecular and cellular outcomes, including the effect of different mutations on 
SATB2 mRNA and protein levels to be efficiently compared. Importantly, this in vitro 
system allows for reasonably high throughput testing of pharmacological agents. 
To facilitate patient treatment, it will be important to elucidate how variability in 
individual disease pathogenesis contributes to SAS phenotypes. This variability may 
derive from the type of molecular alteration to the SATB2 locus, differences in genetic 
background, or even differences in lifestyle. Although therapies attempting to 
exogenously supplement reduced protein levels have achieved little success (Dietz, 
2010), it may be possible to increase the endogenous amount of active protein in several 
ways. For example, in individuals with nonsense pathogenic variants, low levels of 
SATB2 are thought to result from nonsense mediated decay of prematurely terminated 
mRNA transcripts. Several pharmacological agents are now being used to promote “read-
through” of stop codons, thus increasing levels of full-length mRNA (Baradaran-Heravi, 
et al., 2017; Landfeldt, et al., 2018; Roy, et al., 2016). This is an especially attractive 
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avenue for treatment; however, not all nonsense mutations may be equally amenable to 
these treatments as sequences around the mutation may affect read-through activity 
(Bolze, et al., 2017). The power of testing multiple different nonsense mutations in an 
hiPSC in vitro system has great potential to elucidate the details of this potential 
therapeutic mechanism. Of note, loss of function mutations may be amenable to some 
treatment types that would not alleviate the effects of dominant negative mutations. Also 
important to consider, knowing that SATB2 has an important role in early 
neurodevelopment as it has been demonstrated in mice models, the degree of correction 
or reversal of cognitive and speech deficits even if achieving normalization of SATB2 
protein levels in potential human patients treated at later ages could be limited.  
SATB2 function is affected by both post-transcriptional regulation by microRNAs 
(miRNAs) and post-translational modification via sumoylation (Deng, et al., 2013; 
Dobreva, et al., 2003; Wei, et al., 2012). While miRNAs regulate amounts of SATB2 
protein, sumoylation affects SATB2 activation potential and association with endogenous 
MARs in vivo (Dobreva, et al., 2003). Sumoylation targets SATB2 to the nuclear 
periphery (Dobreva, et al., 2003). Therefore, inhibiting sumoylation may increase the 
amount of active SATB2 in association with MARs.  
Another promising approach for treatment of SAS is to focus on modifiers that 
buffer or compensate for reductions in protein function (Chen, et al., 2016). In mice, loss 
of Satb2 dysregulates the expression of multiple miRNAs involved in memory and 
synaptic plasticity (Jaitner, et al., 2016). The effects of dietary supplementation with 
phospholipidic concentrates of krill oil and buttermilk on the expression of miRNAs in 
hippocampal neurons have been studied in murine models (Crespo, et al., 2018). Finally, 
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neurological defects in SAS patients have been reported to share molecular and cellular 
mechanisms with other neurodevelopmental or neurodegenerative diseases such as 
schizophrenia and Alzheimer’s disease (Whitton, et al., 2018). Therefore, similar 
treatments could be explored for these diseases where shared molecular mechanisms are 
identified. 
8. CONCLUSION  
In this mutation update, we present data from 158 SAS individuals and review the current 
state of knowledge and future prospects on human SATB2 alterations. The 120 unique 
variants from 155 unrelated families range from single nucleotide variations to complex 
genomic rearrangements involving the entire coding region of SATB2. While germline 
mosaicism has been found in some instances, most pathogenic variants have been 
confirmed to be de novo. Missense pathogenic variants are often found, and for those 
studied functionally, are predicted to act as loss-of-protein function pathogenic variants. 
Almost invariably, the diagnosis of SAS is made after molecular investigations are 
performed and for individuals with genomic coding variants, next generation sequencing 
technologies are most often used. Through our extensive review of individuals with SAS, 
we present an emerging phenotype that appears more recognizable with age. Our broad 
molecular and clinical descriptions of individuals with SATB2 should help clinicians and 
families establish the diagnosis of SAS and develop future therapies.  
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FIGURES 
Figure 1. Schematic representation of the spectrum of SATB2 variants previously 
described and from this study. A. Splicing and coding exonic pathogenic variants. 
Splicing variants are represented along the genomic structure of SATB2 gene according to 
NM_015265.3 including 12 exons (boxes) and introns (black horizontal lines). Exonic 
pathogenic variants are illustrated according to changes at the protein level (p.) by 
corresponding mutation types as follows: green squares for missense variants, red 
diamonds for frameshift variants, and yellow circles for nonsense variants. Codons 239 
and 283 for nonsense (6 each), and 389 (12 individuals) and 399 (7 individuals) for 
missense variants are affected by the highest number of pathogenic variants. Diagrams 
were constructed using Illustrator for Biosequence (IBS1.0.1). B. SATB2 intragenic 
rearrangements. Full boxes correspond to deletions while lighter rectangles to 
duplications. In case of recurrence of the same exon being involved, number of 
occurrence is indicated next to the rearrangement.  
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Figure 2. A. Broad halluces from 4 different individuals. B. Composite images of 
individuals with nonsense, missense, and frameshift variants. Across all 3 images a flat 
philtrum with thin vermillion of the upper lip can be recognized.  
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Table 1. SATB2 variants found in individuals with SATB2-associated syndrome 
previously reported and from this study (Numbering is according to the cDNA sequence 
(GenBank entry NM_015265.3). 
Variant 
type 
Position DNA variant Predict
ed 
effect 
on 
protein 
Unre
lated 
fami
lies 
in 
our 
coho
rt 
Unre
lated 
fami
lies 
in 
the 
liter
atur
e 
Variant 
Reference 
(dbSNP, 
ClinVar) 
Refer
ences 
Nonsense Exon 3 c.124G>T  p.Gly42*  1 RCV000486598
.1; 
rs1064793947 
Zarate 
et al., 
2017; 
Zarate 
et al., 
2018a 
 
Exon 4 c.346G>T  p.Gly116
* 
 1  Zarate 
et al., 
2018a; 
Scott 
et al.  
 
Exon 5 c.390T>A  p.Tyr130
* 
 1  Benga
ni, 
Zarate 
et al., 
2018a 
 
Exon 6 c.505C>T  p.Gln169
* 
 1  Zarate 
et al., 
2018a; 
Scott 
et al.  
 
Exon 7 c.688A>T p.Lys230
* 
 1  Visser
s et al.  
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Exon 8 c.715C>T  p.Arg239
*  
3 3 RCV000002627
.6; 
RCV000256175
.2; rs137853127 
Leoyk
lang et 
al.; 
This 
study 
 
Exon 8 c.748C>T p.Gln250
* 
 1 RCV000708552
.1 
Zarate 
et al., 
2015 
 
Exon 8 c.847C>T p.Arg283
* 
2 4 RCV000190685
.3; 
RCV000254800
.2; 
RCV000686152
.1; rs797044874 
Zarate 
et al., 
2015; 
Kikuir
i et 
al.; 
This 
study 
 
Exon 8 c.868C>T p.Gln290
* 
2  RCV000413829
.1; 
RCV000624904
.1; 
rs1057518496 
This 
study  
 
Exon 8 c.988C>T p.Gln330
* 
1   This 
study 
 
Exon 8 c.997C>T p.Gln333
* 
1  RCV000599413
.1 
This 
study 
 
Exon 8 c.1135C>T p.Gln379
* 
1   This 
study 
 
Exon 8 c.1171C>T  p.Gln391
* 
 1 RCV000708554
.1 
Zarate 
et al., 
2018a; 
Scott 
et al.  
 
Exon 9 c.1255C>T p.Gln419
* 
 1  Zarate 
et al., 
2017, 
Zarate 
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et al., 
2018a, 
Scott 
et al. 
 
Exon 9 c.1285C>T p.Arg429
* 
1 3 RCV000307104
.1; rs886041847 
Benga
ni et 
al.; 
This 
study 
 
Exon 9 c.1375C>T p.Arg459
*  
1 4 RCV000625170
, 
RCV000680089
.2, 
RCV000719613
.1 
Benga
ni et 
al.; 
This 
study 
 
Exon 10 c.1495A>T  p.Lys499
* 
 1 RCV000224980
.1; rs878853163 
Zarate 
et al., 
2018a, 
Bowli
ng et 
al., 
Scott 
et al. 
 
Exon 11 c.1756C>T p.Gln586
* 
1   This 
study 
  
Exon 12 c.2074G>T p.Glu692
* 
  1 RCV000708559
.1 
Benga
ni et 
al. 
Missense Exon 4 c.185T>A p.Val62A
sp 
 1 RCV000479021
.1; 
rs1064796649 
Zarate 
et al., 
2018a 
 
Exon 4 c.257T>G p.Leu86
Arg 
1   This 
Study 
 
Exon 4 c.287T>G p.Leu96
Arg 
 1 RCV000485845
.1; 
rs1064795247 
Zarate 
et al., 
2018a 
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Exon 4 c.346G>CŐ p.Gly116
Arg 
 1 RCV000494383
.1; 
rs1131691672 
Zarate 
et al., 
2017; 
Zarate 
et al., 
2018a 
 
Exon 5 c.392T>A p.Val131
Glu 
 1 RCV000485195
.1; 
rs1064794638 
Zarate 
et al., 
2018a 
 
Exon 8 c.760C>T p.His254
Tyr 
1   This 
study 
 
Exon 8 c.983C>A p.Ala328
Asp 
 1  Farwe
ll et 
al. 
 
Exon 8 c.1102G>T p.Val368
Phe 
1   This 
study  
 
Exon 8 c.1136A>C p.Gln379
Pro 
1   This 
study  
 
Exon 8 c.1142T>G  p.Val381
Gly 
 1 RCV000708553
.1 
Rauch 
et al.  
 
Exon 8 c.1157C>T p.Ala386
Val 
 1  Benga
ni, 
Zarate 
et al., 
2018a 
 
Exon 8 c.1165C>T p.Arg389
Cys 
5 5 RCV000430827
.1; 
RCV000623230
.1; 
RCV000656508
.2; 
rs1057521083 
Benga
ni et 
al.; 
This 
study 
 
Exon 8 c.1166G>T p.Arg389 1 1  Benga
ni et 
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Leu al.; 
This 
study 
 
Exon 8 c.1169C>T p.Thr390
Ile 
1 1 RCV000199456
.1; rs863224917 
Zarate 
et al. 
2018a, 
2018b
; This 
study 
 
Exon 9 c.1174G>C p.Gly392
Arg 
 1  Zarate 
et al. 
2018a, 
2018b 
 
Exon 9 c.1175G>A p.Gly392
Glu 
1  RCV000489186
.1; 
rs1085308028 
This 
study  
 
Exon 9 c.1181T>C p.Leu394
Ser 
 1  Benga
ni et 
al.  
 
Exon 9 c.1186G>C p.Glu396
Gln 
 1 RCV000708555
.1 
Lee et 
al. 
 
Exon 9 c.1196G>A p.Arg399
His 
2 2 RCV000413401
.1; 
rs1057518190 
Benga
ni, 
Zarate 
et al., 
2018a; 
Scott 
et al.; 
This 
study 
 
Exon 9 c.1196G>T p.Arg399
Leu 
2   This 
study  
 
Exon 9 c.1196G>C p.Arg399
Pro 
 1 SCV000847591.
1; 
rs1057518190 
Zarate 
et al. 
2018a, 
2018b 
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Exon 9 c.1204G>A p.Glu402
Lys 
 1  Benga
ni et 
al. ; 
Zarate 
et al., 
2018a 
 
Exon 9 c.1253T>G p.Met418
Arg 
1   This 
study  
 
Exon 9 c.1286G>A p.Arg429
Gln 
1 3 RCV000300452
.2; 
RCV000708556
.1; rs886041516 
Zarate 
et al., 
2017; 
Zarate 
et al., 
2018a; 
This 
study 
 
Exon 10 c.1541A>G p.Gln514
Arg 
1   This 
study 
 
Exon 11 c.1543G>A p.Gly515
Ser 
 1 SCV000778507.
1 
Benga
ni et 
al. 
 
Exon 11 c.1554T>G p.Cys518
Trp 
1   This 
study  
 
Exon 11 c.1564C>T p.Arg522
Cys 
1   This 
study 
 
Exon 11 c.1696G>A p.Glu566
Lys 
 1 RCV000482629
.1; 
RCV000656509
.1; 
rs1064795530 
Benga
ni et 
al. 
 
Exon 12 c.1903G>T p.Asp635
Tyr 
1   This 
study  
  
Exon 12 c.1964C>T p.Pro655   1 RCV000502290 Zarate 
et al., 
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Leu .1 2017; 
Zarate 
et al., 
2018a 
Framesh
ift 
Exon 3 c.9_16del p.Arg4Gl
ufs*68 
1   This 
study 
 
Exon 3 c.19dupA p.Ser7Ly
sfs*68 
1  RCV000519084
.1; 
RCV000709933
.1;  
This 
study  
 
Exon 4 c.245_263del p.Ala82G
lyfs*30 
1   This 
study 
 
Exon 4 c.334delG p.Ala112
Profs*6 
1   This 
study  
 
Exon 5 c.400delG p.Ala134
Hisfs*17 
 1  Zarate 
et al., 
2017; 
Zarate 
et al., 
2018a 
 
Exon 6 c.482delA p.Lys161
Serfs*19 
 1 RCV000479959
.1; 
rs1064793820 
Zarate 
et al., 
2017; 
Zarate 
et al., 
2018a 
 
Exon 6 c.583dupT p.Cys195
Leufs*14 
 1  Zarate 
et al., 
2017; 
Benga
ni et 
al.; 
Zarate 
et al., 
2018a, 
2018b 
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Exon 6 c.594_595delCC p.Gln199
Glufs*9 
 1  Benga
ni et 
al. 
 
Exon 8 c.808_809delCA p.Gln270
Valfs*33 
 1 RCV000623347
.1 
Zarate 
et al., 
2018a; 
Scott 
et al.  
 
Exon 8 c.816delT p.His273
Thrfs*21 
 1  Zarate 
et al., 
2017; 
Zarate 
et al., 
2018a 
 
Exon 8 c.832delC p.His278
Thrfs*16 
1   This 
study 
 
Exon 8 c.1131_1132del
GT 
p.Ser378
Profs*18 
 1 RCV000209866
.1; rs875989830 
Zarate 
et al., 
2018a 
 
Exon 8 c.1132_1133ins
AC 
p.Ser378
Tyrfs*36 
1   This 
study 
 
Exon 9 c.1196delG p.Arg399
Leufs*14 
1  RCV000624362
.1 
This 
study  
 
Exon 9 c.1203dupA  
p.Glu402
Argfs*35 
 1  Benga
ni et 
al.  
 
Exon 9 c.1311_1314dup
GGAG  
p.Arg439
Glyfs*38 
 1 SCV000845949.
1 
Zarate 
et al., 
2018a 
 
Exon 10 c.1478_1479del
AG 
p.Gln493
Argfs*19 
 1  Kikuir
i et al.  
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Exon 10 c.1498delG 
Mosaic 
p.Val500
Cysfs*46 
1   This 
study 
 
Exon 10 c.1511_1512ins
CAAGCCT  
p.Phe505
Lysfs*10 
1   This 
study  
 
Exon 10 c.1515delT p.Phe505
Leufs*41 
 1 RCV000255520
.1; rs886039740 
Zarate 
et al., 
2018a; 
Scott 
et al.  
 
Exon 11 c.1574delA p.Glu525
Glyfs*21 
 1  Benga
ni et 
al.  
 
Exon 11 c.1592dupA  p.Asn531
Lysfs*21 
 1 RCV000533352
.1 
Zarate 
et al., 
2018a 
 
Exon 11 c.1627delC p.Arg543
Alafs*3 
 1 RCV000496200
.1; 
rs1135401803 
Cherot 
et al. 
 
Exon 11 c.1639_1642deli
nsTTT 
p.Leu547
Phefs*77 
1   This 
study 
 
Exon 11 c.1645delC  
p.Gln549
Serfs*75 
 1  Benga
ni et 
al. 
 
Exon 11 c.1657delG p.Asp553
Metfs*71 
1   This 
study  
 
Exon 11 c.1728delT p.Glu577
Serfs*47 
 1  Zarate 
et al., 
2017; 
Zarate 
et al., 
2018a 
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Exon 12 c.1945dupT p.Ser649
Phefs*40 
 1 SCV000837674.
1 
Zarate 
et al., 
2015; 
Zarate 
et al., 
2018a 
 
Exon 12 c.1972_1973del
AC 
p.Thr658
Hisfs*30 
 1  Zarate 
et al., 
2018a 
 
Exon 12 c.2005dupC p.His669
Profs*20 
 1  Zarate 
et al., 
2018a, 
2018b 
 
Exon 12 c.2018dupA p.His673
Glnfs*16 
 1 RCV000708558
.1 
Boone 
et al. 
  
Exon 12 c.2028delG p.Glu678
Serfs*18 
  1   Zarate 
et al., 
2018a 
In frame 
insertion 
Exon 8 c.929_930insTT
GTAAGGCAAC 
p.Q310de
linsHis 
CysLysA
laThr 
  1   Giliss
en et 
al. 
Splice Exon 4 c.346+2T>G p.?  1 SCV000837664.
1 
Zarate 
et al., 
2015 
 
Exon 5 c.473+1delG p.? 1  RCV000598568
.1 
This 
study  
 
Exon 7 c.598-2A>G p.?  1  Benga
ni et 
al. 
 
Exon 8 c.1173+2T>C p.?  1  Benga
ni et 
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al. 
  
Exon 9 c.1174-2A>G p.?   1   Zarate 
et al., 
2018a, 
Scott 
et al. 
 
Exon 12 c.1741-1G>A p.?  1  Kikuir
i et al.  
Transloc
ation 
t(2;11) cis 
regulatory 
c.? p.?  1  Raing
er et 
al. 
 
t(2;3) cis 
regulatory  
c.? p.?  1  Raing
er et 
al. 
 
t(2;7) 
intron 3 
c.? p.?  1  Brewe
r et al. 
 
t(2:14) 
intron 10 
c.? p.?  1  Tegay 
et al. 
 
t(2;10) 
Intron 8-to 
11 
c.? p.?  1  Baptis
ta et 
al. 
  
t(2;6) c.? p.?   1   Talko
wski 
et al. 
ŐThis variant is also predicted to affect splicing if not resulting in a missense substitution 
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Table 2. Intragenic SATB2 chromosomal abnormalities previously reported and from this 
report 
Abnormalit
y 
Positi
on 
Min sequence 
coordinates hg19 
Size 
(kb) 
Methodology Reference 
Intragenic 
Deletions 
Exons 
9-11 
chr2:200,168,993-
200,203,730 
35 105K Oligo Agilent Balasubrama
nian et al. 
 
Exons 
4-12 
chr2:200,128,960-
200,312,555 
183.6 105K Oligo Agilent Rosenfeld et 
al.  
 
Exons 
3-11 
chr2:200,151,982-
200,325,064 
173.1 105K Oligo Agilent Rosenfeld et 
al.  
 
Exons 
1-11 
chr2:200,151,782-
200,336,956 
185.2 105K Oligo Agilent Rosenfeld et 
al.  
 
Exons 
1-8 
chr2: 200,199,481-
200,340,178 
141 SNP Affymetrix Zarate et al., 
2018a 
 
Exons 
4-8 
chr2: 200,198,963-
200,314,171 
115 SNP Affymetrix This report  
 
Exons 
9-10 
chr2: 200,180,939-
200,200,560 
19.6 OGT 60k oligo Zarate et al., 
2018a 
 
Exons 
1-11 
chr2:200,151,782-
200,336,956 
185 105K Oligo Agilent Zarate et al., 
2018a 
 
Exons 
5-12 
chr2: 200,018,395-
200,246,466 
228 60K Oligo Agilent  Zarate et al., 
2018a 
 
Exon 
9 
chr2:200,190,560-
200,200,832 
10 Affymetrix 750k Zarate et al., 
2018a 
 
Exons 
2-4 
chr2:200,280,770-
200,325,182 
45 OGT 8x60k Zarate et al., 
2018a 
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Exons 
5-8 
chr2:200,212,737-
200,256,585 
44 Affymetrix Cytoscan 
HD 
Zarate et al., 
2018a 
 
Exon 
4 
chr2:200,292,552-
200,302,732 
10.2 Affymetrix Cytoscan 
HD 
Zarate et al., 
2018a 
 
Exons 
4-8 
chr2:200,195,604-
200,315,398 
120 CombiSNP This report  
 
Exons 
8-9 
chr2:200,192,250-
200,230,824 
39 Affymetrix Cytoscan 
HD 
This report  
 
Exons 
1-12 
chr2:200,133,428-
200,450,474 
317 Agilent 8x60K This report  
 
Exons 
7-8 
chr2:200,197,135-
200,242,625 
45.5 Affymetrix Cytoscan 
HD 
This report  
 
Exons 
7-8 
chr2:200,194,727-
200,240,771 
46 180k Cytosure ISCA 
v2 
This report  
 
Exon 
5 
chr2:200,246,407-
200,296,329 
50 Agilent 4x180K, PCR This report  
 
Exons 
1-4 
chr2:200,275,266-
200,344,231 
69 Oligo array + SNP This report  
 
Exon 
7 
chr2:200,222,207-
200,243,660 
21.4 Research WGS (MLPA 
confirmed) 
This report  
 
Exon 
9 
chr2:200,193,421-
200,193,634 
0.213Ő
 
MLPA This report  
Intragenic 
Duplications 
Exon 
4 
chr2:200,278,502-
200,310,272 
32 Affymetrix Cytoscan 
HD, MLPA 
Asadollahi et 
al. 
 
Exon 
4 
chr2:200,256,546-
200,310,885 
54 Affymetrix Cytoscan 
HD, PCR, MLPA 
Kaiser et al. 
This article is protected by copyright. All rights reserved. 
 A
cc
e
pt
e
d 
A
rt
ic
le
 
 
Exons 
5-7 
chr2:200,233,354-
200,255,458 
35 180K Oligo Agilent, 
MLPA 
Lieden et al. 
ŐThe exact location of the breakpoints of this deletion is unknown as the MLPA kit used only covered limited exons.  
Table 3. Demographic and phenotypic features of 158 individuals with SATB2-associated 
syndrome 
Characteristic (N with data) All patients (n = 158) 
Demographics 
 
Male (152)  90 (59.2%) 
Mean age, years (152)  9.5±7.5  
Molecular mechanism 
 
Missense  49 (31.0%) 
Nonsense 38 (24.1%) 
Frameshift 32 (20.3%) 
Splicing  7 (4.4%) 
In frame insertion 1 (0.6%) 
Intragenic deletion 22 (13.9%) 
Translocations 6 (3.8%) 
Intragenic duplication 3 (1.9%) 
Phenotype 
 
Neurodevelopmental abnormalities  
Developmental delay (157) 157 (100%) 
No words for speech (152) 66 (43.4%) 
Autistic behavior (145) 29 (20.0%) 
Dental anomalies (137) 135 (98.5%) 
Sialorrhea (109) 96 (88.1%) 
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Facial dysmorphism (127) 107 (84%) 
Low BMD (46) 33 (71.7%) 
Feeding difficulties (130) 89 (68.5%) 
Hypotonia (114) 67 (58.8%) 
Sleeping difficulties (109) 55 (50.5%) 
Abnormal Neuroimaging (108) 50 (46.3%) 
Sleeping difficulties (145) 66 (45.5%) 
Cleft palate (154) 70 (45.5%) 
Strabismus (143) 51 (35.7%) 
Agitation/Aggressive (145) 45 (31.0%) 
Growth Retardation (144) 44 (30.6%) 
Clinical Seizures (143) 29 (20.3%) 
Hyperactivity (145) 29 (20.0%) 
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